Skip to main content
    C

    Cassava Sciences Inc (SAVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.38
    +0.00 (+0.00%)

    Market Cap: $114.97M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Cassava Sciences Inc (SAVA) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Cassava Sciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$90.97M, operating cash flow was -$32.25M and free cash flow was -$32.83M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$8.60M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $95.39M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$26.59M$69.64M$89.42M$68.03M$24.81M$3.05M$1.57M$2.97M$7.62M$9.18M
    Operating income-$95.39M-$141.45M-$105.96M-$80.02M-$32.87M-$6.45M-$4.96M-$6.66M-$11.95M-$14.96M
    Net income-$90.97M-$24.34M-$97.22M-$76.25M-$32.38M-$6.33M-$4.63M-$6.56M-$11.91M-$14.85M
    EBITDA-$94.45M-$31.72M-$104.43M-$78.72M-$31.90M-$6.42M-$4.90M-$6.59M-$11.88M-$14.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$1.22M$0$0$0$2.35M$0
    Gross profit$0$0$18.98M$0$0$0-$20.53M$0$0$0-$18.73M$0
    Operating income-$9.39M-$11.17M-$13.55M-$11.86M-$45.39M-$24.59M-$29.49M-$30.62M-$61.40M-$19.93M-$22.79M-$27.88M
    Net income-$8.60M-$10.33M-$12.54M-$10.81M-$44.22M-$23.40M-$27.60M-$27.94M$6.16M$25.04M-$20.92M-$25.65M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $95.50M were 80.7% of total assets of $118.36M, against total liabilities of $43.95M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$118.36M$157.53M$151.66M$234.83M$266.78M$94.30M$23.49M$20.14M$10.83M$19.30M
    Current assets$97.71M$136.53M$129.63M$211.23M$244.48M$93.99M$23.35M$20.04M$10.66M$19.07M
    Cash and equivalents$95.50M$128.57M$121.14M$201.01M$233.44M$93.51M$23.08M$19.81M$10.48M$16.61M
    Total liabilities$43.95M$11.83M$14.20M$7.29M$12.87M$2.10M$1.39M$511.00K$1.13M$665.00K
    Short-term debtN/AN/AN/A$104.00K$97.00K$58.00K$90.00KN/AN/AN/A
    Shareholder equity$74.40M$145.70M$137.47M$227.54M$253.91M$92.20M$22.10M$19.63M$9.70M$18.64M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$103.90M$108.37M$118.36M$129.73M$135.38M$140.93M$157.53M$223.75M$243.57M$155.72M$151.66M$172.53M
    Total liabilities$40.29M$40.23M$43.95M$48.16M$47.41M$13.32M$11.83M$57.11M$54.59M$77.12M$14.20M$17.41M
    Cash and equivalents$82.68M$86.57M$95.50M$106.08M$112.38M$117.33M$128.57M$148.98M$207.29M$124.17M$121.14M$142.35M
    Shareholder equity$63.61M$68.14M$74.40M$81.57M$87.97M$127.62M$145.70M$166.64M$188.97M$78.60M$137.47M$155.12M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$32.25M-$116.93M-$82.03M-$77.51M-$30.20M-$5.38M-$2.51M-$4.77M-$8.24M-$12.23M
    Capital expenditures$581.00K$103.00K$414.00K$2.71M$22.21M$0$18.00K$18.00K$18.00K$75.00K
    Free cash flow-$32.83M-$117.03M-$82.44M-$80.23M-$52.41M-$5.38M-$2.53M-$4.79M-$8.26M-$12.31M
    Share repurchases$329.00K$0$0N/AN/AN/A$60.00KN/AN/AN/A
    Investing cash flow-$581.00K-$103.00K-$414.00K-$2.71M-$22.21M$360.00K-$18.00K$0$2.10M-$2.17M
    Financing cash flow-$239.00K$124.47M$2.56M$47.80M$192.34M$75.45M$5.81M$14.10M$0-$284.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$3.85M-$8.88M-$9.75M-$6.22M-$4.95M-$11.34M-$61.27M-$18.30M-$18.24M-$19.13M-$22.32M-$26.53M
    Capital expendituresN/A$0$501.00K$80.00K$0$0$57.00K$17.00K$29.00K$0$41.00K$22.00K
    Free cash flowN/A-$8.88M-$10.25M-$6.30M-$4.95M-$11.34M-$61.32M-$18.31M-$18.27M-$19.13M-$22.36M-$26.55M
    Last 12 quarters

    Frequently Asked Questions About SAVA

    What is Cassava Sciences' annual revenue?

    Cassava Sciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Cassava Sciences profitable?

    No. Cassava Sciences reported net income of -$90.97M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SAVA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$32.25M minus capital expenditures of $581.00K produced free cash flow of -$32.83M.

    How much debt does Cassava Sciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $95.50M.